Servicios Personalizados
Revista
Articulo
Indicadores
Citado por SciELO
Accesos
Links relacionados
Citado por Google
Similares en SciELO
Similares en Google
Compartir
Revista Colombiana de Cardiología
versión impresa ISSN 0120-5633
Resumen
MACHADO-DUQUE, Manuel E.; GAVIRIA-MENDOZA, Andrés y MACHADO-ALBA, and Jorge E.. Prevalence of lipid-lowering drug use. Rev. Colomb. Cardiol. [online]. 2021, vol.28, n.1, pp.14-17. Epub 19-Mar-2021. ISSN 0120-5633. https://doi.org/10.24875/rccar.m21000003.
Introduction:
Among the main causes of death in Colombia, Latin America, and the general population are pathologies of cardiovascular origin, which have an important relationship with dyslipidemias.
Objective:
The objective of the study was to establish the prevalence of the use of lipid-lowering drugs in a Colombian population during 2016.
Material and methods:
A cross-sectional study was conducted using a population database of the Colombian Health System between January and June 2016. Site: outpatients of Colombia. Participants. Researchers considered all patients who had received this class of drug to establish the prevalence of the use of lipid-lowering drugs. Main measurements. Prevalence of use of lipid-lowering drugs.
Results:
From a population of 4,328,688 patients, a total of 282,002 were prescribed a lipid-lowering drug; the mean age was 64.2 ± 13.3 years and women comprised 50.4% of the users. The estimated prevalence of lipid-lowering drug use was 6.5%. Statins (86.3%) were the most commonly used lipid-lowering drugs (atorvastatin: 81.0%, lovastatina: 14.4%) followed by fibrates (13.1%) and ezetimibe (0.6%).
Conclusions:
A low proportion of people are being treated with lipid-lowering drugs, according to the estimated prevalence of dyslipidemia.
Palabras clave : Statins; Hypercholesterolemia; Epidemiology; Pharmacology.